EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Biomarker and updated clinical data for RP1 plus nivolumab in anti–PD-1–failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade

C. Robert, P.K. Bommareddy, T.M. Wise-Draper, J.J. Sacco, G.K. In, E. Muñoz Couselo, D. Schadendorf, J. Niu, G.M. Beasley, B. Chmielowski, M.M. Milhem, T.L. Bowles und 10 weitere

EJC Skin Cancer · 2026 · 4 · 100800

DOI: 10.1016/j.ejcskn.2026.100800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EJC Skin Cancer, 2026. Verfasst von C. Robert und 21 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Robert, C., Bommareddy, P., Wise-Draper, T., Sacco, J., In, G., Couselo, E. M., Schadendorf, D., Niu, J., Beasley, G., Chmielowski, B., Milhem, M., Bowles, T., Tsai, K., Lebbé, C., Gaudy-Marqueste, C., Samson, A., Zhu, J., Viana, M., Tucci, C., …, & Wong, M. (2026). Biomarker and updated clinical data for RP1 plus nivolumab in anti–PD-1–failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade. EJC Skin Cancer, 4, 100800. https://doi.org/10.1016/j.ejcskn.2026.100800

Vancouver

Robert C, Bommareddy P, Wise-Draper T, Sacco J, In G, Couselo EM, et al. Biomarker and updated clinical data for RP1 plus nivolumab in anti–PD-1–failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade. EJC Skin Cancer. 2026;4:100800. doi:10.1016/j.ejcskn.2026.100800

BibTeX
@article{Robert2026,
  author = {Robert, C. and Bommareddy, P.K. and Wise-Draper, T.M. and Sacco, J.J. and In, G.K. and Couselo, E. Muñoz and Schadendorf, D. and Niu, J. and Beasley, G.M. and Chmielowski, B. and Milhem, M.M. and Bowles, T.L. and Tsai, K.K. and Lebbé, C. and Gaudy-Marqueste, C. and Samson, A. and Zhu, J. and Viana, M. and Tucci, C. and Paratala, B. and Hou, J.W. and Wong, M.K.},
  title = {Biomarker and updated clinical data for RP1 plus nivolumab in anti–PD-1–failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade},
  journal = {EJC Skin Cancer},
  year = {2026},
  volume = {4},
  pages = {100800},
  doi = {10.1016/j.ejcskn.2026.100800}
}
Kostenlos starten →